UNICREDIT BANK/CALL/FRESENIUS MEDICAL CARE/65/0.1/19.03.25 Stock

Warrant

DE000HD4Z6U5

Real-time BOERSE MUENCHEN 09:46:27 2024-06-17 EDT
0.017 EUR -10.53% Intraday chart for UNICREDIT BANK/CALL/FRESENIUS MEDICAL CARE/65/0.1/19.03.25
Current month-13.64%
1 month-52.50%
Date Price Change
24-06-17 0.017 -10.53%
24-06-14 0.019 -5.00%
24-06-13 0.02 -23.08%
24-06-12 0.026 +13.04%
24-06-11 0.023 0.00%

Real-time BOERSE MUENCHEN

Last update June 17, 2024 at 09:46 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying FRESENIUS MEDICAL CARE AG
IssuerLogo Issuer UniCredit UniCredit
WKN HD4Z6U
ISINDE000HD4Z6U5
Date issued 2024-04-24
Strike 65
Maturity 2025-03-19 (275 Days)
Parity 10 : 1
Emission price 0.076
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.052
Lowest since issue 0.013

Company Profile

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Sector
-
More about the company

Ratings for Fresenius Medical Care AG

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Fresenius Medical Care AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
38.63 EUR
Average target price
39.97 EUR
Spread / Average Target
+3.48%
Consensus